Allergan Recalls Eye Treatments Amid Safety Concerns
August 24 2015 - 10:20AM
Dow Jones News
Allergan PLC said it is recalling certain lots of eye-treatment
ointments sold in the U.S. under the Refresh, Lacri-Lube and other
brands amid concerns about patient safety.
In a news release Monday, Allergan said the recall is in
response to a small number of customer complaints of a black
particle, which potentially can be introduced into the product when
the cap of the aluminum tube is unscrewed.
The company said complaints include 12 reports of a foreign body
in the eye, two reports of eye irritation and two reports of
product contamination.
Allergan said the company is contacting retailers and
wholesalers who have been shipped the recalled product lots to
initiate the recall.
Consumers with affected lots of Refresh, Lacri-Lube, Refresh
P.M., FML and Belphamide are requested to stop using the products
and return them to Allergan. Consumers also are urged to contact
their physician or health-care provider about any problems related
to use of the recalled products.
Actavis PLC completed its roughly $66 billion deal for the maker
of wrinkle treatment Botox in March, forming one of the top 10 drug
companies by sales. The combined Dublin-based pharmaceutical
company renamed itself as Allergan in June.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 24, 2015 10:05 ET (14:05 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
